Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
About this item
Full title
Author / Creator
Litton, Jennifer K , Rugo, Hope S , Ettl, Johannes , Hurvitz, Sara A , Gonçalves, Anthony , Lee, Kyung-Hun , Fehrenbacher, Louis , Yerushalmi, Rinat , Mina, Lida A , Martin, Miguel , Roché, Henri , Im, Young-Hyuck , Quek, Ruben G.W , Markova, Denka , Tudor, Iulia C , Hannah, Alison L , Eiermann, Wolfgang and Blum, Joanne L
Publisher
United States: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
United States: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
Among patients with breast cancer and germline mutations in the
BRCA
DNA repair pathway genes, the poly(adenosine diphosphate–ribose) inhibitor talazoparib provided a significant benefit over standard chemotherapy with respect to progression-free survival.
Alternative Titles
Full title
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_2091889118
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2091889118
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMoa1802905
